| 4.03 Data as of May 24 |  -0.05 / -1.23%Today’s Change | 2.65 Today|||52-Week Range 5.36 | -14.44% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $469.8M |
Company Description
Sequenom, Inc. designs, develops, manufactures and markets innovative technology, instrumentation and tests that target and serve discovery and clinical research and clinical molecular diagnostics markets. The company operates its business through two segments: Molecular Diagnostics and Genetic Analysis. The Molecular Diagnostics segment researches, develops and commercializes noninvasive molecular diagnostic tests for noninvasive womens' health-related and prenatal diagnostics, ophthalmology, oncology, infectious diseases, and other medical conditions disorders and diseases. The Genetic Analysis segment designs, markets and provides maintenance services for the proprietary MassARRAY system, comprised of hardware, software applications, consumable chips and reagents which are marketed to premier clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies. It provides genetic analysis products that translate genomic science into solutions for biomedical research, agricultural applications, molecular medicine, non-invasive prenatal diagnostics research and clinical utility. Sequenom Applications include translational research, oncology, agricultural genomics and in vitro diagnostics for prenatal and retinal disorders. The company was founded in 1994 and is headquartered in San Diego, CA.
Employees
Shareholders
| Other institutional | 43.44% |
| Mutual fund holders | 30.46% |
| Individual stakeholders | 17.70% |
Top Executives
| Harry F. Hixson, Jr., PhD | Chairman & Chief Executive Officer |
| William J. Welch, MBA | President & Chief Operating Officer |
| Paul V. Maier, MBA | Chief Financial Officer |
| Allan T. Bombard, MD, MBA | Chief Medical Officer |
| Charles R. Cantor, PhD | Chief Scientific Officer |
.
